{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(11)"],"submitter":["Hernandez-Rodriguez J"],"pubmed_abstract":["<h4>Background</h4>Unprotected and fragile elderly people in nursing homes experienced the highest mortality rates during the initial coronavirus disease 2019 (COVID-19) pandemic.<h4>Objective</h4>Our aim was to study the role of two oral anti-inflammatory drugs, colchicine and prednisone, in elderly patients with COVID-19 in geriatric centers.<h4>Methods</h4>A phase II/III, randomized, controlled, multicenter clinical trial was performed in a geriatric population comparing the efficacy and safety of an oral combination of prednisone (60 mg/day for 3 days) and colchicine (at loading doses of 1-1.5 mg/day for 3 days, followed by 0.5 mg/day for 11 days) with the standard treatment, based on intravenous dexamethasone. Primary endpoints assessed the efficacy in reducing death or the modified e"],"journal":["Clinical drug investigation"],"pagination":["949-964"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9521010"],"repository":["biostudies-literature"],"pubmed_title":["FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities."],"pmcid":["PMC9521010"],"pubmed_authors":["Lopez-Guerra N","Aibar J","Blanco JL","Carbonell I","Pujol E","Capdevila-Reniu A","Barilaro G","Salazar A","Gomez B","Hospital-Vidal T","Afonso FJ","Ortega J","Zamora C","Sacanella E","Segui F","Domenech G","Sapena V","Aparicio L","Costafreda M","Illa M","Cajiao K","Luzko-Scheid IS","Mayor MI","FRAGILE-COLCOVID19 Study Group","Masanes F","Domenech M","Casanovas G","Asensio Y","Calvo J","Araujo O","Guasch N","Lopez-Soto A","Aldea-Pares A","Milisenda JC","Saavedra OM","Gomez-Caverzaschi V","Macaya I","Ventosa H","Tome-Perez A","Feliu M","Tuset M","Ventura R","Masdeu G","Montes V","Sanchez-Palacios V","Matas-Garcia A","Moreno PJ","Gabara C","Espinosa G","Ribot J","Naval J","Gomez-Urbano V","Rios-Garces R","Gonzalo T","Rivero E","Pilarcikova S","Ladino A","Vinas-Esmel E","Guillen M","Pahisa A","Inzitari M","Morancho A","Canueto MDC","Montoya-Rodes M","Pellice M","Montero M","Torres-Elorza M","Gamez G","Azuaga AB","Benages N","Guio AM","Joyera M","Sanchez-Buitrago A","Foncillas A","Moragas N","Rodriguez-Nunez O","de-Daniel-Bisbe A","Alemany X","Lledo GM","Hernandez-Rodriguez J","Garcia-Ortega A","Prieto-Gonzalez S","Marco D","Sanz A","Garcia-Gutierrez C","Cuzco C","Duran-Sanclemente J","San Miguel A","Garcia-Jarque L","Grafia I"],"additional_accession":[]},"is_claimable":false,"name":"FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.","description":"<h4>Background</h4>Unprotected and fragile elderly people in nursing homes experienced the highest mortality rates during the initial coronavirus disease 2019 (COVID-19) pandemic.<h4>Objective</h4>Our aim was to study the role of two oral anti-inflammatory drugs, colchicine and prednisone, in elderly patients with COVID-19 in geriatric centers.<h4>Methods</h4>A phase II/III, randomized, controlled, multicenter clinical trial was performed in a geriatric population comparing the efficacy and safety of an oral combination of prednisone (60 mg/day for 3 days) and colchicine (at loading doses of 1-1.5 mg/day for 3 days, followed by 0.5 mg/day for 11 days) with the standard treatment, based on intravenous dexamethasone. Primary endpoints assessed the efficacy in reducing death or the modified e","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-05-27T19:14:03.984Z","creation":"2025-02-19T03:24:14.971Z"},"accession":"S-EPMC9521010","cross_references":{"pubmed":["36173596"],"doi":["10.1007/s40261-022-01201-2"]}}